Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Nemtabrutinib PK in Healthy Participants
NCT06772818Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nemtabrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL) and 2 more (2 arms), sponsored by Merck & Co. Primary endpoint: Area under the concentration-time curve from time 0 extrapolated to infinity. Started Oct 2023; status: completed.
02
Drugs
nemtabrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)mantle cell lymphoma (MCL)follicular lymphoma (FL)Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT06772818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06772818.